Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinom
- PDF / 1,021,927 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 190 Views
Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life S. Deschuymer1 · D. Nevens1,5 · F. Duprez2 · J. F. Daisne1,3 · M. Voordeckers4 · W. De Neve2 · S. Nuyts1 Accepted: 2 September 2020 © Springer Nature Switzerland AG 2020
Abstract Purpose A randomized trial was initiated to investigate whether a reduction of the dose to the elective nodal sites would result in less toxicity and improvement in Quality of Life (QoL) without compromising tumor control. This paper aimed to compare QoL in both treatment arms. Methods Two-hundred head and neck cancer patients treated with radiotherapy (RT) or chemo-RT were randomized (all stages, mean age: 60 years, M/F: 82%/18%). The elective nodal volumes of patients randomized in the experimental arm were treated up to a 40 Gy equivalent dose. In the standard arm, the elective nodal volumes were treated up to a 50 Gy equivalent dose. The QoL data were collected using The European Organization for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and the EORTC Head and Neck Cancer module (H&N35). Results A trend toward less decline in QoL during treatment was observed in the 40 Gy arm compared to the 50 Gy arm. Statistically significant differences for global health status, physical functioning, emotional functioning, speech problems, and trouble with social eating in favor of the 40 Gy arm were observed. A clinically relevant better outcome in the 40 Gy arm was found for physical functioning at the end of therapy. Conclusion QoL during RT for head and neck cancer tends to be less impaired in the 40 Gy arm. However, reducing the dose only on the elective neck does not result in clinically relevant improvement of QoL. Therefore, additional treatment strategies must be examined to further improve the QoL of HNSCC patients. Keywords Quality of life · Head and neck cancer · Radiotherapy · Elective nodes · Dose reduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11136-020-02628-w) contains supplementary material, which is available to authorized users. * S. Nuyts [email protected] 1
Present Address: Department of Radiation Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
2
Department of Radiotherapy‑Oncology, Ghent University Hospital, Ghent, Belgium
3
Department of Radiation Oncology, Université Catholique de Louvain, CHU-UCL-Namur, Site Ste‑Elisabeth, Namur, Belgium
4
Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussel, Belgium
5
Present Address: Department of Radiation Oncology, Iridium Kanker Netwerk, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Introduction Radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC) has made enormous progress over the past decades and treatment intensification led to improved clinical outcome [1]. U
Data Loading...
